Inovio Pharmaceuticals, Inc.
INO
$2.04
$0.094.62%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.52M | -19.69M | -19.38M | -25.17M | -32.24M |
| Total Depreciation and Amortization | 741.70K | 743.50K | 775.80K | 765.90K | 828.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.87M | -3.15M | -327.00K | -184.30K | 1.42M |
| Change in Net Operating Assets | 94.40K | -4.77M | -731.00K | -2.86M | 1.78M |
| Cash from Operations | -20.81M | -26.87M | -19.66M | -27.44M | -28.21M |
| Capital Expenditure | -30.90K | -59.40K | 0.00 | 0.00 | -452.30K |
| Sale of Property, Plant, and Equipment | -- | -- | 59.30K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.31M | 7.60K | 34.59M | 14.08M | 10.42M |
| Cash from Investing | 5.28M | -51.80K | 34.64M | 14.08M | 9.97M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Common Stock | 0.00 | 1.10M | 13.08M | 667.10K | 17.13M |
| Repurchase of Common Stock | -34.80K | -74.20K | 0.00 | -6.40K | -240.10K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 16.06M | 0.00 | 16.15M |
| Cash from Financing | -34.80K | 1.03M | 29.15M | 660.60K | 33.03M |
| Foreign Exchange rate Adjustments | -- | -- | 0.00 | 0.00 | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.56M | -25.90M | 44.13M | -12.70M | 14.79M |